Opendata, web and dolomites

FasNaGel

NOVEL THERAPEUTIC NANOHYDROGEL FOR ACUTE AND CHRONIC PAIN TREATMENT TARGETED TO THE NERVES FASCIA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FasNaGel project word cloud

Explore the words cloud of the FasNaGel project. It provides you a very rough idea of what is the project "FasNaGel" about.

2014    prevent    coming    market    containing    nanostructured    population    losses    properly    provides    feasibility    effectiveness    imed    life    porous    euros    med    perform    anti    start    consists    medicines    time    disorders    acid    acute    people    fast    absences    hyaluronic    biocompatible    personal    days    exit    20    inflammatory    quality    negative    made    policies    thorough    track    medical    fasnagel    carrier    80    wrongly    healthcare    patients    chronic    suffers    estimates    report    nanomedicinal    reduce    post    60    100    30    surgery    chronification    sme    functional    world    greatest    gdp    treatment    149    biodegradable    commercialization    injectable    multiply    plane    direct    drug    pain    steroidal    unemployment    team    indirect    operative    sickness    worldwide    disability    enormous    mill    deducting    102    professional    few    recovery    prematurely    size    marketing    huge    271    billion    total    depression    first    works    labour    validation    started    staff    productivity    hydrogel   

Project "FasNaGel" data sheet

The following table provides information about the project.

Coordinator
I+MED S.COOP. PEQUENA 

Organization address
address: CALLE ALBERT EINSTEIN 15
city: VITORIA-GASTEIZ
postcode: 1510
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://imasmed.com/portfolio-items/programas-investigacion/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    I+MED S.COOP. PEQUENA ES (VITORIA-GASTEIZ) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Worldwide chronic pain conditions are by far the greatest cause of disability. It has an enormous negative impact on quality of life and on personal and professional plane. Chronic pain is an important cause of depression, more sickness absences at work, productivity losses, unemployment, etc.). Chronic pain is one of the major reasons (30%) why people exit the labour market prematurely. 20% of current population in Europe suffers from chronic pain (102 mill.) and up to 50 % of that pain comes from wrongly treated acute post-operative pain. The total direct and indirect healthcare costs for chronic pain disorders in Member States have an EU average of 2.4 % of GDP and a cost of 271 billion euros per year. When acute pain is not properly treated in the first few days, it can become chronic. About 40-60% of patients report pain chronification after surgery. Current medicines do not prevent chronic pain from the start and have side effects. “Fast track” approaches have started to take the lead in pain management policies. Based on these approaches I Med´s team works since 2014 in the development of FasNaGel, a new nanomedicinal product, unique in the world. It consists of a biocompatible and biodegradable injectable carrier, made of porous nanostructured hyaluronic acid hydrogel containing a non-steroidal anti-inflammatory drug that i) efficiently, provides a 100% of functional recovery after surgery in one third of the time, ii) is easy-to-use by medical staff, and the most important iii) increases by 80% the treatment effectiveness. FasNaGel will reduce the overall treatment costs in Europe, deducting indirect costs coming from acute pain up to €149 billion. The objective of this proposal is to be able to perform a thorough feasibility study for the validation of the production and commercialization of this novel product. FasNaGel marketing will have a huge of a SME such as iMed, who estimates to multiply the team size by 8 in 7 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FASNAGEL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FASNAGEL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More